Stockscreener 앱 받기
148.43
2.20%
3.20
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Sepsis Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Which Is a Better Investment, Novartis AG (ADR) or Pfizer Inc. Stock? - AAII.com
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips - Investing.com
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips By Investing.com - Investing.com Canada
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed - ChartMill
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria - ChartMill
Novartis AG (NVS) Stock Price, Trades & News - GuruFocus
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) - ChartMill
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): Is its innovative drug pipeline strong enough to unlock new upside - AD HOC NEWS
Novartis AG (MEX:NVSN) Bonds - GuruFocus
Novartis AG (MEX:NVSN) Dividend - GuruFocus
Novartis AG stock (CH0012005267): Is its focused pharma strategy strong enough to unlock new upside? - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why Google Discover changes matter more now - AD HOC NEWS
Novartis AG Stock Baskets | MEX:NVSN - GuruFocus
Novartis AG Stock Operating Data - GuruFocus
Novartis AG (ADR) stock (CH0012005267): Why its innovative drug pipeline matters more now for invest - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why does its innovative drug pipeline matter more now for in - AD HOC NEWS
NVS Stock Quote Price and Forecast - CNN
Book value per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
Novartis AG stock (CH0012005267): Is its Innovative Medicines focus strong enough to unlock new upsi - AD HOC NEWS
Novartis AG stock: Why Fabhalta momentum matters for investors now - AD HOC NEWS
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill
Novartis AG stock: What investors should know about its steady pharma powerhouse status - AD HOC NEWS
Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com
Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for N - AD HOC NEWS
Novartis AG Stock: Resilient Pharma Leader with Strong Fundamentals and Strategic Growth Ahead for I - AD HOC NEWS
Novartis AG Stock Historical Valuations - GuruFocus
1.64%
자본화:
|
볼륨(24시간):